Registration Statement

Prelude Therapeutics Inc Filed 2021-11-12 Acc 0001193125-21-328040

Documents 1

2024-02-16 S-3 Registration Statement
2021-11-19 UPLOAD SEC-generated Letter
2021-11-18 4 EVP, Chief of Clinical Affairs sold 28,751 shares at an average $15.88 ($456,532)
2021-11-12 10-Q Quarterly Report
2021-11-12 8-K Results of operations · Executive or director change · Regulation FD disclosure
2021-11-12 S-3 Registration Statement

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

Loading d221420ds3.htm…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…